Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Sanofi SA (SANF)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
88.05 +0.46    +0.53%
16:20:45 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 965
  • Bid/Ask: 88.05 / 88.12
  • Day's Range: 87.26 - 88.05
Type:  Equity
Market:  Italy
ISIN:  FR0000120578 
Sanofi 88.05 +0.46 +0.53%
IndustryBiotechnology & Drugs
SectorHealthcare
Employees

99412

Equity Type

ORD

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Contact Information

Phone +33-1-53774000
Fax 1-53774463

Top Executives

Name Age Since Title
Olivier Charmeil 58 2020 Executive Vice President - General Medicines, Member of the Executive Committee
Philippe Luscan 58 2015 Executive Vice President - Global Industrial Affairs, Member of the Executive Committee
Serge Weinberg 69 2015 Independent Chairman of the Board
Carole Piwnica 63 2010 Independent Director
Karen Linehan 62 2014 Executive Vice President - Legal Affairs and General Counsel, Member of the Executive Committee
Fabienne Lecorvaisier 58 2013 Independent Director
Patrick Kron 67 2014 Independent Director
Diane Souza 68 2016 Independent Director
Thomas Sudhof 65 2016 Independent Director
Melanie Lee 62 2017 Independent Director
William J. Sibold 54 2017 Executive Vice President - Sanofi Genzyme, Member of the Executive Committee
Jean-Baptiste Chasseloup De Chatillon 55 2018 Chief Financial Officer, Executive Vice President, Member of the Executive Committee
John C. Reed 62 2018 Executive Vice President - Global Head of Research and Development, Member of the Executive Committe
Christophe Babule 55 2019 Director
Paul Hudson 53 2019 Chief Executive Officer, Member of the Executive Committee, Director
Gilles Schnepp 62 2020 Independent Director
Rachel Duan 50 2020 Independent Director
Lise Kingo 59 2020 Independent Director
Natalie Bickford 50 2020 Chief Human Resource Officer, Executive Vice President, Member of the Executive Committee
Julie Van Ongevalle 46 2020 Executive Vice President, Member of the Executive Committee
Arnaud Robert 47 2020 Executive Vice President - Chief Digital Officer, Member of the Executive Committee
Thomas Triomphe 46 2020 Executive Vice President - Head of Sanofi Pasteur, Member of the Executive Committee
Barbara Lavernos - 2021 Director
Wolfgang Laux - 2021 Director, Employee Representative
Tran Yann - 2021 Director, Employee Representative
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SASY Comments

Write your thoughts about Sanofi
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Greg Greg
Greg Greg Dec 11, 2020 9:36
Saved. See Saved Items.
This comment has already been saved in your Saved Items
there is no future for it
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email